Your session is about to expire
← Back to Search
Regorafenib for Acute Myeloid Leukemia
Study Summary
This trial is studying regorafenib as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative neoplasms).
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 495 Patients • NCT02024607Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are eligible, have a compatible donor, and are willing to undergo a procedure called Hematopoietic Stem Cell Transplantation (HSCT).You have a condition that makes it difficult for your body to absorb nutrients from food.Your blood pressure is consistently high, even with the best medication to control it.You have a heart condition that is currently active or could cause significant health problems.You have had a stroke, blood clot in your veins or arteries, or other serious blood vessel problems within the last 6 months.You have a wound, ulcer, or broken bone that is not healing properly.You have severe kidney problems and need dialysis treatment.You have a condition called epilepsy and need to take medication for it.You have received an organ transplant in the past or have known allergies to the study drugs or any substances used in this trial.You have conditions like substance abuse, medical problems, psychological issues, or social difficulties that could make it hard for you to take part in the study or for the researchers to accurately evaluate the study results.You have a heart condition called coronary artery disease that is currently causing problems.You have a heart condition that causes irregular heartbeats and requires medication other than beta blockers or digoxin.You have advanced cancer that has come back or is not responding to treatment. This includes specific types of leukemia, myelodysplastic syndrome, and myelofibrosis that have not improved with previous treatments.
- Group 1: Regorafenib
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What medical conditions is Regorafenib typically prescribed to treat?
"Regorafenib is the go-to medication for treating many anti-vegf related issues. Additionally, this drug can be beneficial in treating advanced directives, sorafenib, and unresectable gastrointestinal stromal tumor."
What risks are associated with taking Regorafenib?
"Taking into consideration the experimental nature of this study, with few data points attesting to its efficacy and safety, Regorafenib has been assigned a score of 1."
Are there still openings for volunteers in this clinical trial?
"This trial has concluded its recruitment phase as of September 4th, 2020. Initially posted on April 17th 2017, this study is no longer accepting patients for their clinical research. For those who are still looking to join an ongoing medical trial there are currently 508 studies enrolling participants with leukemia and 59 trials recruiting people undergoing treatment with regorafenib."
Is this pioneering research a unique endeavor?
"Research into regorafenib has spanned since 2014, when the original Bayer-sponsored trial was conducted with 38 participants. Subsequent trials have seen the drug receive Phase 2 approval and 59 active studies across 418 cities and 30 countries."
Have there been any other experiments conducted on Regorafenib?
"Presently, 59 trials are underway exploring the efficacy of Regorafenib. Of those studies, 7 have achieved Phase 3 status. A majority of these tests for this treatment take place in Commack, New york; though there are over 1200 sites running investigations with it worldwide."
What is the current recruitment figure for this trial?
"This research project is not currently recruiting potential participants. The posting was initially made on April 17th 2017 and revised lastly in September 4th 2020. If you are seeking alternative trials, presently there are 508 studies with open enrollment for patients suffering from leukaemia, myelocytic acute and 59 clinical trials requiring Regorafenib volunteers."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger